<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/369">
<title>Dr Xavier TD</title>
<link>http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/369</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/370"/>
</rdf:Seq>
</items>
<dc:date>2026-04-09T08:57:33Z</dc:date>
</channel>
<item rdf:about="http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/370">
<title>Adverse Drug Reactions (ADR) necessitating modification of multi-drug therapy (MDT) in Hansens disease: a retrospective study from Kerala, India</title>
<link>http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/370</link>
<description>Adverse Drug Reactions (ADR) necessitating modification of multi-drug therapy (MDT) in Hansens disease: a retrospective study from Kerala, India
Ambooken, Betsy; George, Sandhya; Azeez, Neema; Asokan, N; Xavier, TD
Objective:&#13;
To assess the frequency and type of adverse drug reactions (ADR) that necessitated modification of multi-drug therapy (MDT) in Hansen’s disease, with emphasis to find out the interval between initiation of MDT and the occurrence of ADR.&#13;
&#13;
Design:&#13;
A retrospective analysis of case records of patients diagnosed with Hansen’s disease (HD) and registered for MDT in a tertiary care institution between 2010 and 2015. Clinical details and laboratory data were collected using a proforma.&#13;
&#13;
Results:&#13;
One hundred and ninety-six patients were registered for treatment during the study period. We analysed 150 records that met the inclusion criteria. Thirty-six among them (24%) had ADR that needed modification of MDT. The most common ADR was haemolytic anemia (19 patients; 12.7%) followed by hepatitis (14 patients; 9.3%). The most serious ADR was agranulocytosis (three patients; 2%). Adverse effects were more common (72%) during the initial 2 months of MDT compared to later months. (P = 0.004).
</description>
<dc:date>2017-06-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
